MindWalk Holdings Corp.

Name: MindWalk Holdings Corp.
Address: 823 Congress Avenue, Suite 300, Austin, TX, 78701, US
Telephone: +18006204187

Home
United States
Austin, TX
MindWalk Holdings Corp.

All-in-one biointelligence ecosystem unifying Bio-Native AI, deep data, and advanced lab research to drive new breakthroughs in biologics discovery

MindWalk is a global biologics discovery company integrating Bio-Native AI, deep data, and advanced lab research to help accelerate discovery and development of therapeutic, anti-drug, and diagnostic antibodies, peptide-based therapies, vaccines, and beyond. We deliver end-to-end solutions spanning target exploration, discovery, engineering, characterization, production, and humanization—available

as full-service partnerships, existing-asset co-development, or modular SaaS access. We partner with leading biotech and pharmaceutical organizations, applying our unified biointelligence ecosystem to advance next-generation biologics for human health.

03/05/2026

🗞️ INDUSTRY NEWS UPDATE: AI is playing a growing role in healthcare and life sciences, as adoption trends continue to expand across the sector.

Read: ordnl.link/oKW74VH

🇺🇸 :

03/04/2026

Our LensAI™ platform, powered by our core HYFT® technology, captures and reasons over biological context to link sequences, functions, experimental outcomes, and scientific evidence into a continuously learning system with the potential to transform drug discovery.

Explore: ordnl.link/NBtot36

🇺🇸 :

02/23/2026

📩 NEWSLETTER SIGN-UP: Don't miss out. Our exclusive newsletter delivers the latest insights and updates on how our AI platforms are changing the game in drug discovery and development.

Sign up: ordnl.link/IeaK31k

🇺🇸 :

02/20/2026

AI and automation are at the core of healthtech trends in 2025. We're continuing to explore AI-driven drug discovery in 2026 and beyond.

See what our journey's been like: ordnl.link/iILdY3c

🇺🇸 :

02/18/2026

As reported in last month's news release, the defining feature of our platform is selectivity: the ability to distinguish toxic protein conformations from healthy ones. This plays a crucial role in mitigating development risk in neurodegenerative drug programs.

Explore: ordnl.link/mRIQMls

🇺🇸 :

01/28/2026

𝗣𝗿𝗲𝘀𝘀 𝗥𝗲𝗹𝗲𝗮𝘀𝗲: 𝗠𝗶𝗻𝗱𝗪𝗮𝗹𝗸 𝗔𝗽𝗽𝗹𝗶𝗲𝘀 𝗛𝗬𝗙𝗧® 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 𝘁𝗼 𝗗𝗲𝘁𝗲𝗰𝘁 𝗙𝘂𝗻𝗰𝘁𝗶𝗼𝗻𝗮𝗹 𝗔𝗱𝗷𝗮𝗰𝗲𝗻𝗰𝘆 𝗟𝗶𝗻𝗸𝗲𝗱 𝘁𝗼 𝗣𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 𝗥𝗶𝘀𝗸 𝗶𝗻 𝗔𝗜-𝗗𝗲𝘀𝗶𝗴𝗻𝗲𝗱 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀

MindWalk announced an application of its proprietary HYFT® technology designed to identify functional adjacency - meaning different molecules can produce the same therapeutic effect even when sequence comparisons suggest they are unrelated - an emerging source of competitive, legal, and valuation risk in modern drug discovery that sequence-alignment-based analysis often fails to capture.

Using HYFT® technology, MindWalk found a shared biological “signature” in influenza that stays consistent even when the virus’s genetic code changes a lot. This supports MindWalk’s approach to designing vaccine targets aimed at broader protection across strains and shows how HYFT identifies meaningful similarities in biology even when molecules do not look alike at first glance.

“Functional adjacency is now one of the most under-appreciated risks in pharmaceutical R&D. If two molecules deliver the same biological effect, they may compete for the same patient, pursue similar regulatory labels, and undermine perceived differentiation even if their sequences appear unrelated. As AI accelerates protein design, teams can generate many distinct sequences that converge on the same functional outcome, increasing the likelihood of competitive overlap, IP vulnerability, and valuation compression. HYFT is intended to help identify this convergence early by evaluating similarity at the functional level, not only at the sequence level,” said Jennifer Bath, Ph.D., Chief Executive Officer of MindWalk.

𝗦𝗲𝗲 𝗳𝘂𝗹𝗹 𝗿𝗲𝗹𝗲𝗮𝘀𝗲: ordnl.link/47rlKYq

$HYFT

01/15/2026

𝗠𝗶𝗻𝗱𝗪𝗮𝗹𝗸 𝗩𝗮𝗹𝗶𝗱𝗮𝘁𝗲𝘀 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗧𝗮𝗿𝗴𝗲𝘁𝗶𝗻𝗴 𝗣𝗮𝘁𝗵𝗼𝗴𝗲𝗻𝗶𝗰 𝗧𝗗𝗣-𝟰𝟯 𝗶𝗻 𝗡𝗲𝘂𝗿𝗼𝗱𝗲𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝘃𝗲 𝗗𝗶𝘀𝗲𝗮𝘀𝗲

MindWalk announced the discovery and validation of antibodies that selectively target misfolded TDP-43, a key driver in ALS, FTD, and certain Alzheimer’s cases. The work validates our ability to distinguish toxic protein states from healthy biology and reinforces MindWalk’s role as a discovery partner for complex neurodegenerative programs.

𝗦𝗲𝗲 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲: ordnl.link/XcYm7sr 𝗦𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝘀𝘁𝘂𝗱𝘆: ordnl.link/8JuRyzQ

Forward-looking statements apply.

$HYFT

01/13/2026

💉 Explore the milestones that have transformed our understanding of vaccines, from their early beginnings to today’s innovations, in Saloni Dattani's full article in Works in Progress.

Read: ordnl.link/8BjHY2q

🇺🇸 :

12/31/2025

2026 marks a new era of AI-driven healthcare. The entire industry is changing from the ground up, and AI is at the wheel of this progress.

Explore how we’re making an impact: ordnl.link/1okKCwQ

🇺🇸 :

12/29/2025

📩 NEWSLETTER SIGN-UP: Be part of our journey! Get the latest updates as we evolve into a next-generation, bio-native AI company driving innovation in biologics discovery and development.

Subscribe: ordnl.link/I8YVnur

🇺🇸 :

Address

823 Congress Avenue, Suite 300
Austin, TX
78701

Telephone

+18006204187

Website

https://www.mindwalkai.com/

Alerts

Be the first to know and let us send you an email when MindWalk Holdings Corp. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to MindWalk Holdings Corp.:

Shortcuts

Want your business to be the top-listed Engineering Company in Austin?